Literature DB >> 26838737

Expression and clinical significance of IL-17 and IL-17 receptor in ulcerative colitis.

Heng Zhang1,2, Bing Xia1, Jin Li3, Qiu Zhao1, Zhi-Tao Chen2, Rui Zhou1, Jie Wu1.   

Abstract

The purpose of this study was to determine the expression levels of IL-17 in serum and IL-17 receptor (IL-17R) in intestinal mucosa tissue in patients with ulcerative colitis (UC) and controls, and evaluate their relationship with disease activity and explore the role of IL-17 in the patho-genesis of UC. A total of 36 Chinese UC patients and 60 healthy controls were enrolled in this study. Serum IL-17 and C-reactive protein (CRP) levels were determined by ELISA and immunonephelometry, respectively. The IL-17R mRNA expression levels were detected by quantitative PCR. Serum IL-17 levels were significantly elevated in UC patients as compared with those in the healthy controls (P<0.05). Among UC patients, serum IL-17 levels were significantly increased in active phase as compared with those in inactive phase (P<0.05), and correlated with CRP levels (r=0.578, P<0.01). IL-17R expression levels were higher in active UC patients than in healthy controls (P<0.05). It was concluded that IL-17 levels were highly expressed in UC, especially in active phase, and correlated with CRP levels in UC patients.

Entities:  

Keywords:  interleukin-17; interleukin-17 receptor; intestinal mucosa; serum; ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 26838737     DOI: 10.1007/s11596-016-1538-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  22 in total

Review 1.  IL-17 and Th17 Cells.

Authors:  Thomas Korn; Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

2.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

3.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

4.  Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases.

Authors:  Zaruhi Hovhannisyan; Jacquelyn Treatman; Dan R Littman; Lloyd Mayer
Journal:  Gastroenterology       Date:  2010-12-11       Impact factor: 22.682

Review 5.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

6.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 7.  Mucosal cytokine network in inflammatory bowel disease.

Authors:  Akira Andoh; Yuhki Yagi; Makoto Shioya; Atsushi Nishida; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

8.  Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease.

Authors:  L Rovedatti; T Kudo; P Biancheri; M Sarra; C H Knowles; D S Rampton; G R Corazza; G Monteleone; A Di Sabatino; T T Macdonald
Journal:  Gut       Date:  2009-09-08       Impact factor: 23.059

9.  Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection.

Authors:  Deepak A Rao; Raymond E Eid; Lingfeng Qin; Tai Yi; Nancy C Kirkiles-Smith; George Tellides; Jordan S Pober
Journal:  J Exp Med       Date:  2008-12-15       Impact factor: 14.307

10.  Regulation of inflammatory responses by IL-17F.

Authors:  Xuexian O Yang; Seon Hee Chang; Heon Park; Roza Nurieva; Bhavin Shah; Luis Acero; Yi-Hong Wang; Kimberly S Schluns; Russell R Broaddus; Zhou Zhu; Chen Dong
Journal:  J Exp Med       Date:  2008-04-14       Impact factor: 14.307

View more
  4 in total

1.  Based on Network Pharmacology to Explore the Molecular Targets and Mechanisms of Gegen Qinlian Decoction for the Treatment of Ulcerative Colitis.

Authors:  Meiqi Wei; He Li; Qifang Li; Yi Qiao; Qun Ma; Ruining Xie; Rong Wang; Yuan Liu; Chao Wei; Bingbing Li; Canlei Zheng; Bing Sun; Bin Yu
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

2.  Analysis of the Efficacy and Pharmacological Mechanisms of Action of Zhenren Yangzang Decoction on Ulcerative Colitis Using Meta-Analysis and Network Pharmacology.

Authors:  Guosheng Xing; Yufeng Zhang; Xinlin Wu; Hua Wang; Yan Liu; Zhen Zhang; Mingxing Hou; Haibing Hua
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-28       Impact factor: 2.629

3.  Inhibition of the activation of γδT17 cells through PPARγ-PTEN/Akt/GSK3β/NFAT pathway contributes to the anti-colitis effect of madecassic acid.

Authors:  Xinming Yun; Yulai Fang; Changjun Lv; Simiao Qiao; Yu Tao; Yue Dai; Yufeng Xia
Journal:  Cell Death Dis       Date:  2020-09-14       Impact factor: 8.469

4.  Epstein-Barr Virus DNA Exacerbates Colitis Symptoms in a Mouse Model of Inflammatory Bowel Disease.

Authors:  Sirine Andari; Hadi Hussein; Sukayna Fadlallah; Abdo R Jurjus; Margret Shirinian; Jana G Hashash; Elias A Rahal
Journal:  Viruses       Date:  2021-06-29       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.